"My main frustration is that the batches used in Europe and the USA were from different production sites."
Maybe it's not that the Belgium production site was better, but the US standard care was better than the European.
The vitrogrow treatment arm produced good figures, but so did the standard care group. It's that high standard care figure that made the trial fail. If the standard care numbers were poor (or similar to what we have seen in past trials) then we would have passed the trial well with how vitrogrow performed.
We scored a 57 in our round of golf, which would statistically win any competition. But it turned out to be the average score of the hundred odd players playing.
FTT Price at posting:
0.2¢ Sentiment: None Disclosure: Held
